Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA
March-In Rights at a Crossroad: What Biopharma Needs To Know Under Trump Administration
Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more
Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC, USA
Bhavya Bhardwaj
Student, University of Pennsylvania, USA
Patent Strategies for Attenuated Pathogen Vaccines 
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Tom Irving
Partner, Marbury Law Group, USA
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA
Michelle E. O'Brien
Partner, Marbury Law Group, USA
Supported Studies Quid Pro Quo
Many pharmaceutical companies (hereinafter Companies or Company) recognize the importance of supporting external studies and the role they play in fulfilling patients’ needs. High standard ethical research conducted by external...Read more
Ann Turi
Senior Legal Counsel, Legal and Compliance R&D and Medical Legal Team, Gsk, USA
Section 112 Requirements for Life Sciences Patents
35 U.S.C. §112(a) of the US Patent Act is one of the integral parts of the quid pro quo patent system that balances the benefit of disclosure of the invention...Read more
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
A Current Look at the State of Inequitable Conduct and Other Equitable Concerns
Inequitable conduct is an “equitable defense to patent infringement that, if proved, bars enforcement of a patent. ” Therasense, Inc. v. Becton, Dickinson & Co. , 649 F. 3d 1276,...Read more
Tom Irving
Partner, Marbury Law Group, USA
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA
Stacy Lewis
Law Clerk, Finnegan, USA
Jordan Cowger
Finnegan, USA
Melissa Santos
Finnegan, USA
Induced Infringement under US Patent Law
Induced infringement finds its basis in 35 U.S.C. § 271(b) and holds a person, liable if he actively causes infringement, even if the actor himself is not the direct infringer....Read more
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Jatin Jalundhwala
Joint President Legal and Company Secretary, Adani Group, India
Written Description Requirement of Patentability
One of the requirements for an invention to be patentable is written description, which requires that the invention be described in sufficient detail for one of ordinary skill in the...Read more
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Blocking Effect of the Blocking Act?
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch Waxman Act 1984, was enacted in 1984 to balance the privileges offered to brand...Read more
Anagha Tendulkar
In-house Patent Counsel, Cipla, India